Analysts expect that AC Immune SA (NASDAQ:ACIU) will report sales of $12.93 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for AC Immune’s earnings. The highest sales estimate is $18.71 million and the lowest is $7.14 million. The company is scheduled to announce its next earnings results on Friday, March 16th.

On average, analysts expect that AC Immune will report full year sales of $12.93 million for the current year, with estimates ranging from $11.02 million to $22.87 million. For the next year, analysts expect that the firm will post sales of $25.28 million per share, with estimates ranging from $25.09 million to $25.47 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for AC Immune.

Separately, Zacks Investment Research downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a report on Thursday, November 16th.

AC Immune (NASDAQ ACIU) opened at $12.27 on Monday. AC Immune has a fifty-two week low of $6.03 and a fifty-two week high of $15.00.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Belpointe Asset Management LLC bought a new stake in shares of AC Immune during the 3rd quarter worth $571,000. Janney Montgomery Scott LLC bought a new stake in shares of AC Immune during the 3rd quarter worth $134,000. Wells Fargo & Company MN bought a new stake in shares of AC Immune during the 3rd quarter worth $111,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AC Immune during the 2nd quarter worth $127,000. 17.12% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “AC Immune SA (ACIU) Expected to Announce Quarterly Sales of $12.93 Million” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/ac-immune-sa-aciu-expected-to-announce-quarterly-sales-of-12-93-million.html.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.